CORRESP Filing
ONCOLYTICS BIOTECH INC
Date: April 1, 2026 · CIK: 0001129928 · Accession: 0001104659-26-038540
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-294811
Letter
ONCOLYTICS BIOTECH INC.
4350 Executive Drive, Suite 325
San Diego, California 92121
VIA EDGAR
April 1, 2026
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Attention: Tim Buchmiller
Re: Oncolytics Biotech Inc.
Registration Statement on Form S-3
Filed April 1, 2026
File No. 333-294811
To the addressee set forth above:
Pursuant to Rule 461 of the U.S. Securities Act of 1933, as amended, Oncolytics Biotech Inc. (the “Company”) hereby requests acceleration of the effective date of its registration statement on Form S-3 (File No. 333-294811) (the “Registration Statement”) to 4:30 p.m. Eastern Time on April 3, 2026, or as soon thereafter as practicable.
Please contact Christopher J. Clark of Latham & Watkins LLP, counsel to the Company, at (202) 637-2374 or Christopher.J.Clark@lw.com, as soon as the Registration Statement has been declared effective, or if you have any other questions or concerns regarding this matter.
Very truly yours,
ONCOLYTICS BIOTECH INC.
Show Raw Text
CORRESP
1
filename1.htm
ONCOLYTICS BIOTECH INC.
4350 Executive Drive, Suite 325
San Diego, California 92121
VIA EDGAR
April 1, 2026
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Attention:
Tim Buchmiller
Re: Oncolytics Biotech Inc.
Registration Statement
on Form S-3
Filed April 1, 2026
File No. 333-294811
To the addressee set forth above:
Pursuant to Rule 461 of the
U.S. Securities Act of 1933, as amended, Oncolytics Biotech Inc. (the “Company”) hereby requests acceleration of the effective
date of its registration statement on Form S-3 (File No. 333-294811) (the “Registration Statement”) to 4:30 p.m. Eastern Time
on April 3, 2026, or as soon thereafter as practicable.
Please contact Christopher
J. Clark of Latham & Watkins LLP, counsel to the Company, at (202) 637-2374 or Christopher.J.Clark@lw.com, as soon as the Registration
Statement has been declared effective, or if you have any other questions or concerns regarding this matter.
Very truly yours,
ONCOLYTICS BIOTECH INC.
By:
/s/ Kirk Look
Name:
Kirk Look
Title:
Chief Financial Officer
cc: Jared Kelly, Chief Executive Officer
Christopher J. Clark, Latham & Watkins LLP